Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.56 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.49 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | TFEB | P19484 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2528986 | 1.00 | NFE2L2 (0.56) | NFE2L2TRPM8KDM4EPTGER4PTGER3 | |
| SCHEMBL457033 | 0.82 | NFE2L2 (0.79) | NFE2L2TRPM8KDM4EKMT2AGAA | |
| SCHEMBL1056670 | 0.82 | NFE2L2 (0.79) | NFE2L2TRPM8KDM4EKMT2AGAA | |
| SCHEMBL6776487 | 0.82 | NFE2L2 (0.79) | NFE2L2TRPM8KDM4EKMT2AGAA | |
| SCHEMBL636344 | 0.81 | SRC (0.52) | NFE2L2TRPM8KMT2ACYP1A2NPC1 | |
| SCHEMBL638265 | 0.80 | SRC (0.51) | NFE2L2TRPM8KDM4EKMT2AGAA | |
| SCHEMBL7422566 | 0.80 | NFE2L2 (0.56) | NFE2L2TRPM8KDM4EKMT2ACYP1A1 | |
| SCHEMBL2433729 | 0.79 | NFE2L2 (0.54) | NFE2L2TRPM8KDM4EPTGER4PTGER3 | |
| SCHEMBL7358834 | 0.79 | PRMT1 (0.69) | NFE2L2TRPM8NPC1RAB9A | |
| SCHEMBL2433728 | 0.79 | NFE2L2 (0.54) | NFE2L2TRPM8KDM4EPTGER4PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344010-B2 | Fused imidazole derivatives as TRPV3 antagonist | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-01-01 | — | — | US | disclosed |
| US-20110257193-A1 | FUSED IMIDAZOLE DERIVATIVES AS TRPV3 ANTAGONIST | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2011-10-20 | — | — | US | disclosed |
| US-20090291950-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2008006052-A2 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | GOVEK STEVEN P (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257193-A1 | FUSED IMIDAZOLE DERIVATIVES AS TRPV3 ANTAGONIST | TRPV3, TRPV1, TRPV2 | NFE2L2 709/4885TRPM8 15/4885KDM4E 3411/4885 |
| US-20090291950-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | NFE2L2 917/4885TRPM8 4539/4885KDM4E 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.